和血明目片联合雷珠单抗治疗RVO伴黄斑水肿的临床研究

Clinical Study of Hexue Mingmu Tablets Combined with Lucentis in the Treatment of RVO Complicated with Macular Edema

目的:探讨和血明目片联合雷珠单抗治疗视网膜静脉阻塞(RVO)伴黄斑水肿对患者黄斑形态学变化及预后随访。方法:选择启东市中医院2018年12月-2021年6月收治RVO伴黄斑水肿病患者128例(128只眼)为研究对象,按照随机数字表法将其分为试验组(64只眼)和对照组(64只眼),每组64例。试验组采用和血明目片联合雷珠单抗治疗,对照组采用雷珠单抗治疗。对比两组视力疗效、最佳矫正视力变化、黄斑厚度变化、出血面积、视网膜渗漏变化及不良反应发生情况。结果:治疗后3个月,试验组视力提高率高于对照组(84.38% vs 73.44%)(P<0.05)。治疗后3个月,两组最佳矫正视力均高于治疗前,且试验组高于对照组,差异均有统计学意义(P<0.05)。治疗后3个月,两组黄斑厚度和出血灶面积均低于治疗前,且试验组均低于对照组,差异均有统计学意义(P<0.05)。试验组治疗后3个月渗漏面积总改善率高于对照组(89.06% vs 73.44%)(P<0.05)。两组治疗过程中均未出现任何不良反应情况。结论:RVO伴黄斑水肿患者选择和血明目片联合雷珠单抗治疗可提高患者视力,并且还能减轻黄斑水肿,改善视网膜渗漏面积,安全性高,值得临床大力推广及应用。

Objective:To investigate the patients’ macular morphological changes and prognosis of Hexue Mingmu Tablets combined with Lucentis in the treatment of retinal vein occlusion (RVO) complicated with macular edema.Method:A total of 128 patients (128 eyes) with RVO complicated with macular edema who admitted to Qidong Hospital of Traditional Chinese Medicine from December 2018 to June 2021 were selected as the research objects,and they were randomly divided into the experimental group (n=64,64 eyes) and the control group (n=64,64 eyes).The experimental group was given Hexue Mingmu Tablets combined with Lucentis,and the control group was given Lucentis.Visual efficacy,changes in best corrected visual acuity,changes in macular thickness,bleeding area,changes in retinal leakage and adverse reactions were compared between two groups.Result:At 3 months after treatment,the visual acuity improvement rate of the experimental group was higher than that of the control group (84.38% vs 73.44%) (P<0.05).At 3 months after treatment,the best corrected visual acuity of two groups were higher than those before treatment,and the experimental group was higher than that of the control group,and the differences were statistically significant (P<0.05).At 3 months after treatment,the macular thickness and bleeding area of two groups were lower than those before treatment,and the experimental group were lower than those of the control group,and the differences were statistically significant (P<0.05).The total improvement rate of leakage area in the experimental group at 3 months after treatment was higher than that in the control group (89.06% vs 73.44%) (P<0.05).There were no adverse reactions in two groups during treatment.Conclusion:The combination of Hexue Mingmu Tablets combined with Lucentis for RVO patients complicated macular edema can improve the visual acuity,alleviate macular edema and improve the area of retinal leakage,which is of high safety and worthy of clinical promotion and application.